Using Birth Tissues to Treat COVID-19? Injecting a Cytokine Storm

By /

covid19 amniotic stem cells

Many providers who use orthobiologics have used various birth tissues to try to help patients heal orthopedic injuries. However, many have also discovered that they’re a two-edged sword. On the one hand, they can enhance healing but on the other, they can also stoke serious inflammation. Now some providers are advocating their use to treat COVID-19. Today I’ll share some data that shows why this is likely the equivalent of Russian Roulette.

Birth Tissues 101

Birth tissues have been used for decades in many types of surgeries. For example, neurosurgeons would often tap the OB ward for pieces of amniotic membrane to replace the covering of the spinal cord called the dura. Ophthalmologists have also used these tissues in corneal repairs. Then about a decade ago, some companies began selling these tissues to promote wound healing. Shortly thereafter, a few companies with no scruples began to claim that their birth tissue products had stem cells, which turned out to be fraudulent as later research showed this to be untrue (1-3).

Our Use of Amnion

In select patients, we have noted that since amniotic membrane products contain growth factors that can promote tendon healing, they can sometimes be added to PRP injections to promote tendon healing. PRP stands for platelet-rich plasma and this is when the doctor takes the patient’s blood and concentrates the healing platelets which also have growth factors. For example, when a patient has a rotator cuff tear, PRP injection precisely into that area can often save them from needing more invasive surgery.

Hence, when we decided to source a single amnion vendor for our entire network of more than 70 U.S. clinics who can help patients avoid shoulder surgery, we used our advanced lab capabilities to test many different products for growth factor and cytokine levels. What we found turned out to be good news or bad news for COVID-19 patients who are now getting offered this stuff as treatment. In fact, what we found could be a dangerous game of Russian Roulette.

The Inflammatory Cytokine Russian Roulette

If you recall from other posts, many hospitalized COVID-19 patients end up with a dangerous “cytokine storm” of inflammation in their lungs which causes respiratory failure. Of the many ways that this could be treated, one of the purposed therapies is a specialized stem cell product that’s made in a lab. Because of the fiction that amniotic tissues contain stem cells, some manufacturers of these birth tissues have taken the position that patients should be given their birth products as a therapy to prevent or treat COVID-19. 

There’s just one serious problem. Our research shows that some of these tissue products have much higher levels of natural inflammatory cytokines. Basically asking for trouble in treating COVID-19.

Our Testing

Given that we have treated many patients with rotator cuff tears and helped them avoid surgery, we began testing amniotic products to help our providers bridge the gap between a patient that just needs a precise PRP injection versus a full stem cell injection procedure. Amnion plus PRP can fill that doughnut hole nicely in our experience. What were we testing for?

First, while every other provider in the country that offers orthobiologics would be at the mercy of the sales reps in buying the right amniotic product, Regenexx has it’s own university-level lab in which to test products. Hence, we began testing different products and different lots of the same product for growth factors like FGF which are known to help tendon cells heal. We also began to notice some disturbing trends in other growth factors associated with inflammation.

Gasoline on a Bonfire

Anyone who has injected patients with amniotic tissue products knows that sometimes they can stoke up severe swelling and inflammation in patients. I call this the gasoline on a bonfire effect. When this data began to come in from our testing we began to see the likely reason why this happens. For example, take the samples we tested below:

These are levels of two inflammatory cytokines in various lots of the same product we tested. Note that sample 1 above is low in both IL-8 and TNF-a. However, lots 2,3, and 4 are high in these “gasoline on a bonfire” inflammatory chemicals.

Amnion and COVID-19

So what would happen if you tried to inject a product like this intravenously into a COVID-19 patient? It would be like throwing gasoline on that cytokine storm bonfire. It could just as easily prime the patient for more severe COVID-19 or if they were already sick, it could put them in the ICU on a ventilator.

The upshot? As our research shows, different lots of the same product contain vastly different levels of inflammatory cytokines. While in a rotator cuff tear patients that may mean more swelling in the area, for a patient trying to prevent or treat COVID-19, that may be enough to cause serious harm. So please avoid using these birth tissue products to protect or treat this disease.



(1) Berger D, Lyons N, Steinmetz, N. In Vitro Evaluation of Injectable, Placental Tissue-Derived Products for Interventional Orthopedics. Interventional Orthopedics Foundation Annual Meeting. Denver, 2015.

(2) Becktell L, Matuska A, Hon S, Delco M, Cole B, Fortier L. Proteomic analysis and cell viability of nine amnion-derived biologics. Orthopedic Research Society Annual Meeting, New Orleans, 2018.

(3) Panero, A, Hirahara, A., Andersen, W, Rothenberg J, Fierro, F. Are Amniotic Fluid Products Stem Cell Therapies? A Study of Amniotic Fluid Preparations for Mesenchymal Stem Cells With Bone Marrow Comparison. The American Journal of Sports Medicine, 2019 47(5), 1230–1235.

This blog post provides general information to help the reader better understand regenerative medicine, musculoskeletal health, and related subjects. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient profiles, outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.

Get health and wellness information from a trusted source.

By submitting the form, you are agreeing that you read and consent to our Privacy Policy. We may also contact you via email, phone, and other electronic means to communicate information about our products and services. We do not sell, or share your information to third party vendors.

Category: Uncategorized

Leave a Reply

Your email address will not be published. Required fields are marked *

5 thoughts on “Using Birth Tissues to Treat COVID-19? Injecting a Cytokine Storm

  1. Marc

    What about the Neil Riordan signature Biologics products? They are different than other birth Tissue products for COVID-19 correct?

    1. Chris Centeno, MD Post author

      No, they are not different. They should NOT be used to treat COVID-19 outside of an FDA approved and supervised clinical trial.

  2. Gary D.

    Dr. Centeno,

    I’m not a medical person, but I did see this news release the other day. Is this the type of technology you’re referencing, or something else? Many thanks.

    NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the first patients have been dosed in the 300-patient randomized placebo-controlled Phase 2/3 trial in the United States of Mesoblast’s allogeneic cellular medicine remestemcel-L in COVID-19 infected patients with moderate to severe acute respiratory distress syndrome (ARDS) on ventilator support.

    Mesoblast holds an Investigational New Drug (IND) application cleared by the FDA for use of remestemcel-L in the treatment of patients with COVID-19 ARDS. The clinical protocol for the Phase 2/3 trial is based on initial promising results from use of remestemcel-L in patients with moderate to severe COVID-19 ARDS under an emergency IND application or expanded access protocol at The Mount Sinai Hospital in New York. The trial will randomize up to 300 ventilator-dependent patients in intensive care units to either remestemcel-L or placebo (1:1) on top of maximal care, in line with specific guidance provided by the United States Food and Drug Administration (FDA) for robust statistical analysis. The primary endpoint is all-cause mortality within 30 days of randomization, with the key secondary endpoint being the number of days alive and off mechanical support. . .

    1. Chris Centeno, MD Post author

      Something completely different.

  3. Dan

    Dr. Cardberry with AMI is pushing IV injections of Predictive Biotech for treatment of COVID-19. He’s even on video saying it.. smh.

    @Marc- NO they are no different then other products AND if you read the insert it says specifically NOT to put it through an IV. Unsure if they are still doing this (don’t know why they would stop) but they make physicians sign an affidavit stating they will not use product through IV.

Is Regenexx Right For You?

Request a free Regenexx Info Packet


Learn about the #1 Stem Cell & Platelet Procedures for treating arthritis, common joint injuries & spine pain.

Join a Webinar


Get fresh updates and insights from Regenexx delivered straight to your inbox.

Subscribe to the Blog


9035 Wadsworth Pkwy #1000
Westminster, CO 80021


Copyright © Regenexx 2021. All rights reserved. | Privacy Policy

*DISCLAIMER: Like all medical procedures, Regenexx® Procedures have a success and failure rate. Patient reviews and testimonials on this site should not be interpreted as a statement on the effectiveness of our treatments for anyone else.

Providers listed on the Regenexx website are for informational purposes only and are not a recommendation from Regenexx for a specific provider or a guarantee of the outcome of any treatment you receive.